Devices for Inhaled Medications Market is Expected to Reach USD Million by 2026
Published | 20 January 2021
According to BlueWeave Consulting, the global Devices for Inhaled Medications market is expected to reach USD million by 2026, growing at a CAGR of XX% during the forecast period (2020-2026). The Inhalers devices are widely used due to their integration with smart technologies. The rising number of smokers, rapidly increasing air pollution and the prevalence of the pulmonary disease is the driver for the growth of global inhaler market. The use of an inhaler for medication has the least side effects and is effective in giving treatment to patients. The devices are widely used in hospitals, clinics, and patient facilities.
Rise in prevalence of respiratory diseases, a key growth driver in the market
The prevalence of respiratory diseases (COPD, asthma, emphysema, etc. is growing, the demand for first aid medicines during sudden asthma attacks is rising, and the demand for effective short-term medicines is increasing rapidly. Furthermore, manufacturers will concentrate on developing improved portable inhalers, and government awareness campaigns are expected to fuel demand growth for COPD and asthma symptoms.
Bronchodilators segment is leading the device for Inhaled medication market
Growing incidence rates of respiratory and pulmonary diseases such as asthma and COPD, increasing awareness among individuals, increasing government and health care initiatives, increasing demand for bronchodilator medicines, and the adoption of unhealthy lifestyles are the key drivers for the growth of the global bronchodilator market.
Homecare in the end-user segment holds the largest share of the Devices for Inhaled Medications
Due to the growing geriatric population, increased per capita spending, and increasing knowledge of respiratory diseases, the segment of home care centers is expected to report the highest growth rate during the forecast period. A Healthcare First organization report found that more than 3.4 million people in the U.S. receive eligible home health care services from Medicare because of the growing elderly population and the rising prevalence of chronic health problems in the nation.
Meter dose Inhaler (MDI) for Inhaled Medications occupy the largest share of the Devices for Inhaled Medications market
The rapid growth of the healthcare industries and pharmaceutical sectors is the main factor driving the demand for metered-dose inhalers. The prevalence of diseases connected to the respiratory system, such as chronic obstructive pulmonary diseases, asthma, chronic respiratory diseases, and others has increased in recent years. Due to the increase in awareness among people about advanced respiratory devices that have beneficial features compared to conventional treatment methods, the demand for metered-dose inhalers has increased, thus propelling the market growth.
Regional insights
The global Devices for Inhaled Medications market is segmented into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Due to the growing cases and prevalence of the pulmonary disease, the North American region is leading the inhaler industry, and the region also has a large number of companies. Due to rapid developments in technology, the introduction of the smart inhaler concept, and the existence of a large number of companies, the European region is the second-largest captor of the global inhaler market.
The leading players” in the Devices for Inhaled Medications market includes 3M Company, Agilent technologies, Aradigm Corporation, AstraZeneca plc, Bespak, Beximo pharmaceuticals ltd., Boehringer Ingelheim gmbh, Cipla inc., Drive Devilbiss Healthcare, GE Healthcare, GlaxoSmithKline, H&T presspart manufacturing ltd, Hovione, Mannkind corporation, Manta devices LLC, Midascare, Novartis ag, Omega life sciences, Omron healthcare Europe b.v, Philips n.v, Propeller health, Pulmatrix, inc, Savara inc, Spyryx biosciences inc, Teicos pharma ltd, Teijin limited, Teva respiratory LLC, Vitalograph. Companies engaged in the global inhaler market provide a wide array of nasal inhalers, nebulizers, dry powder inhalers, and metered dose inhalers. A large number of companies are engaged in the development of smart inhalers to make the devices handier and smarter.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global Devices for Inhaled Medications market size & forecast. The report promises to provide recent technology trends of Devices for the Inhaled Medications market and industry insights that help decision-makers to make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
About Us
BlueWeave Consulting provides all kinds of Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions company providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
Get Help
Related Report
Publish Date: January 2021
The global Devices for Inhaled Medications market is expected to reach USD million by 2026, growing at a CAGR of % during the forecast period (2020-2026).
Relevant Press Releases
- Global Pulse Oximeters Market to Rise at a Remarkable CAGR of 10.1% by 2027
- India Ventilator Market to Witness 9.1% CAGR during 2022–2028
- Saudi Arabia Medical Device Sterilization Market Size Set to Expand at CAGR of 9% to Cross USD 505 Million by 2029
- France Hearing Aids Market to Grow at a CAGR of 7.2% until 2028
- Global Vital Signs Monitoring Devices Market Size Expands at Significant CAGR of 8.33% During 2023–2029 to Touch USD 9.57 Billion by 2029